Vanguard Capital Management
COGT icon

Vanguard Capital Management’s Cogent Biosciences COGT Stock Holding History

Vanguard Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$238M Buy
7,448,057
+35,727
+0.5% +$1.32M 0.01% 986
2026
Q2 		$287M Buy
7,412,330
+517,371
+8% +$18.1M 0.01% 940
2026
Q1 		$265M Buy
+6,894,959
New +$255M 0.01% 918

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Capital Management's COGT Position: Q3 2026 in Review

Vanguard Capital Management increased its Cogent Biosciences (COGT) stake by 0.48% in Q3 2026, buying an estimated $1.32M and bringing the position to 7,448,057 shares worth $238M. The position accounts for 0.01% of the portfolio, ranked #986.

Vanguard Capital Management first reported a position in COGT in Q1 2026 and has held it in 3 quarters since. The position peaked at $287M in Q2 2026. 202 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Vanguard Capital Management held 7,448,057 shares of Cogent Biosciences worth $238M as of Q3 2026.
  • Vanguard Capital Management bought 35,727 Cogent Biosciences shares in Q3 2026, an estimated $1.32M.
  • Cogent Biosciences made up 0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #986 holding.
  • Vanguard Capital Management first reported a position in Cogent Biosciences in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Cogent Biosciences position peaked at $287M in Q2 2026.
  • 202 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.